Form 8-K - Current report:
SEC Accession No. 0001628280-24-047406
Filing Date
2024-11-13
Accepted
2024-11-13 06:12:19
Documents
15
Period of Report
2024-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xfor-20241113.htm   iXBRL 8-K 29611
2 EX-99.1 a991pressreleasedatednovem.htm EX-99.1 113241
6 x4logo.jpg GRAPHIC 4345
  Complete submission text file 0001628280-24-047406.txt   290610

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20241113.xsd EX-101.SCH 1785
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20241113_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20241113_pre.xml EX-101.PRE 13048
17 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20241113_htm.xml XML 2824
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 241451014
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)